Maravai Lifesciences (MRVI) | Financial Analysis & Statements
Maravai Lifesciences Holdings Inc. Small-cap Healthcare
TL;DR: Financial Overview - Revenue, Profits & Key Metrics
Latest Quarterly: Dec 2025Income Metrics
Revenue
49.9M
Gross Profit
12.8M
25.75%
Operating Income
-22.5M
-45.18%
Net Income
-63.0M
-126.37%
EPS (Diluted)
$-0.24
Balance Sheet Metrics
Total Assets
770.6M
Total Liabilities
397.9M
Shareholders Equity
372.7M
Debt to Equity
1.07
Cash Flow Metrics
Operating Cash Flow
-52.3M
Free Cash Flow
-24.9M
Revenue & Profitability Trend
Quarter Income Flow
Dec 31, 2025
Annual Income Flow
2025
Maravai Lifesciences Income Statement From 2021 to 2025
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | 185.7M | 259.2M | 288.9M | 883.0M | 799.2M |
| Cost of Goods Sold | 151.8M | 150.9M | 148.7M | 169.0M | 140.6M |
| Gross Profit | 34.0M | 108.3M | 140.2M | 714.0M | 658.7M |
| Gross Margin % | 18.3% | 41.8% | 48.5% | 80.9% | 82.4% |
| Operating Expenses | |||||
| Research & Development | 17.4M | 19.2M | 17.3M | 18.4M | 15.2M |
| Selling, General & Administrative | 145.1M | 161.8M | 151.4M | 129.3M | 100.1M |
| Other Operating Expenses | - | - | - | - | - |
| Total Operating Expenses | 162.5M | 181.0M | 168.7M | 147.6M | 115.3M |
| Operating Income | -128.5M | -72.7M | -28.5M | 566.4M | 543.4M |
| Operating Margin % | -69.2% | -28.0% | -9.9% | 64.1% | 68.0% |
| Non-Operating Items | |||||
| Interest Income | 11.4M | 27.4M | 27.7M | 2.3M | 0 |
| Interest Expense | 27.0M | 47.7M | 45.9M | 20.4M | 30.3M |
| Other Non-Operating Income | -90.9M | -168.5M | 664.4M | 3.1M | 17.6M |
| Pre-tax Income | -235.0M | -261.5M | 617.7M | 551.5M | 530.8M |
| Income Tax | -4.2M | -1.9M | 756.1M | 60.8M | 61.5M |
| Effective Tax Rate % | 0.0% | 0.0% | 122.4% | 11.0% | 11.6% |
| Net Income | -230.8M | -259.6M | -138.4M | 490.7M | 469.2M |
| Net Margin % | -124.2% | -100.2% | -47.9% | 55.6% | 58.7% |
| Key Metrics | |||||
| EBITDA | -60.8M | 9.2M | 715.6M | 602.4M | 583.3M |
| EPS (Basic) | - | $-1.05 | $-0.90 | $1.67 | $1.59 |
| EPS (Diluted) | - | $-1.05 | $-0.90 | $1.67 | $1.56 |
| Basic Shares Outstanding | - | 137906000 | 131919000 | 131545000 | 114791000 |
| Diluted Shares Outstanding | - | 137906000 | 131919000 | 131545000 | 114791000 |
Income Statement Trend
Join Our United States Telegram Channel
Get Instant Market Updates: 52-Week High/Low Alerts, Breakout Notifications & Expert Stock Analysis Delivered To Your Phone. Join Traders Making Informed Decisions Daily!
Maravai Lifesciences Balance Sheet From 2021 to 2025
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Assets | |||||
| Current Assets | |||||
| Cash & Equivalents | 216.9M | 322.4M | 575.0M | 632.1M | 551.3M |
| Short-term Investments | - | - | - | - | - |
| Accounts Receivable | 25.5M | 38.5M | 54.6M | 138.6M | 117.5M |
| Inventory | 40.5M | 50.1M | 51.4M | 43.2M | 51.6M |
| Other Current Assets | 13.4M | 18.1M | 17.8M | 25.8M | 19.7M |
| Total Current Assets | 296.3M | 429.1M | 699.9M | 847.9M | 740.0M |
| Non-Current Assets | |||||
| Property, Plant & Equipment | 117.9M | 131.2M | 138.3M | 63.9M | 49.1M |
| Goodwill | 410.4M | 514.7M | 873.0M | 811.3M | 423.1M |
| Intangible Assets | 151.5M | 195.0M | 221.0M | 243.9M | 117.6M |
| Long-term Investments | - | - | - | - | - |
| Other Non-Current Assets | 2.6M | 7.2M | 17.9M | 790.2M | 812.5M |
| Total Non-Current Assets | 474.3M | 579.1M | 787.5M | 1.4B | 1.2B |
| Total Assets | 770.6M | 1.0B | 1.5B | 2.3B | 1.9B |
| Liabilities | |||||
| Current Liabilities | |||||
| Accounts Payable | 2.9M | 12.0M | 10.7M | 6.0M | 8.2M |
| Short-term Debt | 14.2M | 13.7M | 12.9M | 11.7M | 9.7M |
| Current Portion of Long-term Debt | - | - | - | - | - |
| Other Current Liabilities | 1.9M | 1.5M | - | 10.0M | - |
| Total Current Liabilities | 44.9M | 57.0M | 87.5M | 110.1M | 93.8M |
| Non-Current Liabilities | |||||
| Long-term Debt | 350.5M | 363.0M | 598.1M | 573.6M | 565.5M |
| Deferred Tax Liabilities | 2.2M | - | - | - | 0 |
| Other Non-Current Liabilities | 197.0K | 423.0K | 2.4M | 413.0K | 160.0K |
| Total Non-Current Liabilities | 352.9M | 374.1M | 610.1M | 1.3B | 1.3B |
| Total Liabilities | 397.9M | 431.0M | 697.6M | 1.4B | 1.4B |
| Equity | |||||
| Common Stock | 2.6M | 2.5M | 2.5M | 2.6M | 2.6M |
| Retained Earnings | 10.1M | 140.9M | 285.7M | 404.8M | 184.6M |
| Treasury Stock | - | - | - | - | - |
| Other Equity | - | - | - | - | - |
| Total Shareholders Equity | 372.7M | 577.2M | 789.9M | 905.2M | 545.4M |
| Key Metrics | |||||
| Total Debt | 364.7M | 376.7M | 611.0M | 585.3M | 575.2M |
| Working Capital | 251.3M | 372.2M | 612.4M | 737.8M | 646.3M |
Balance Sheet Composition
Maravai Lifesciences Cash Flow Statement From 2021 to 2025
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Operating Activities | |||||
| Net Income | -230.8M | -259.6M | -138.4M | 490.7M | 469.2M |
| Depreciation & Amortization | 60.5M | 56.9M | 48.8M | 38.1M | 33.5M |
| Stock-Based Compensation | 30.2M | 49.4M | 34.6M | 18.7M | 10.5M |
| Working Capital Changes | -5.0M | 8.2M | 74.6M | -712.0K | -163.7M |
| Operating Cash Flow | -139.2M | -141.1M | 103.0M | 580.1M | 392.8M |
| Investing Activities | |||||
| Capital Expenditures | -12.4M | -22.5M | -52.7M | -16.0M | -14.3M |
| Acquisitions | -19.0M | 0 | -69.6M | -238.3M | 120.0M |
| Investment Purchases | - | - | - | - | - |
| Investment Sales | - | - | - | - | - |
| Investing Cash Flow | -31.4M | -22.8M | -122.3M | -267.6M | 105.7M |
| Financing Activities | |||||
| Share Repurchases | - | - | - | 0 | 0 |
| Dividends Paid | - | - | - | - | - |
| Debt Issuance | - | 953.0K | 0 | 8.5M | 0 |
| Debt Repayment | -5.4M | -235.0M | -5.8M | -13.9M | -6.0M |
| Financing Cash Flow | -16.5M | -233.6M | -61.1M | -189.9M | -160.8M |
| Free Cash Flow | -70.7M | -23.7M | 60.7M | 518.9M | 353.7M |
| Net Change in Cash | -187.1M | -397.5M | -80.4M | 122.7M | 337.7M |
Cash Flow Trend
Maravai Lifesciences Key Financial Ratios
Valuation Ratios
P/E Ratio (TTM)
28.39
Forward P/E
-24.25
Price to Book
2.52
Price to Sales
7.29
PEG Ratio
0.85
Profitability Ratios
Profit Margin
-70.41%
Operating Margin
-39.36%
Return on Equity
-48.59%
Return on Assets
-8.83%
Financial Health
Current Ratio
6.60
Debt to Equity
97.85
Beta
0.43
Per Share Data
EPS (TTM)
$-0.90
Book Value per Share
$1.46
Revenue per Share
$1.29
Peer Financial Comparison
| Company | Market Cap | P/E Ratio | P/B Ratio | ROE | Profit Margin | Debt/Equity |
|---|---|---|---|---|---|---|
| MRVI | 1.3B | 28.39 | 2.52 | -48.59% | -70.41% | 97.85 |
| Vertex | 109.4B | 28.40 | 5.92 | 22.54% | 32.94% | 10.91 |
| Regeneron | 81.0B | 18.00 | 2.45 | 14.86% | 31.41% | 9.51 |
| Recursion | 1.9B | -2.44 | 1.64 | -59.54% | 4.45% | 6.89 |
| Capricor | 2.0B | -15.61 | 6.62 | -46.56% | 0.00% | 4.75 |
| Zymeworks | 2.0B | 3.79 | 7.32 | -26.72% | -76.56% | 6.80 |
Financial data is updated regularly. All figures are in the company's reporting currency.






